Continuing Education Activity
Thalidomide is a medication used to manage and treat advanced leprosy and multiple myeloma, and various other solid and hematologic malignancies. It is in the immunomodulatory class of medications. This activity reviews the indication, action, and contraindications for thalidomide as a valuable agent in the treatment of leprosy, multiple myeloma, and other malignancies when applicable. This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent for interprofessional team members managing the care of patients with leprosy, multiple myeloma, and other malignancies and their related conditions.
- Describe the unique molecular composition of thalidomide and how this affects the drug’s therapeutic and adverse effects.
- Identify the most common adverse effects associated with thalidomide therapy.
- Summarize proper treatment and responses to thalidomide toxicity.
- Explain the importance of the interprofessional healthcare team monitoring patients taking thalidomide, especially females of reproductive age.
Historically, thalidomide is best known for its introduction during the 1950s as a sedative and antiemetic marketed to women to treat pregnancy-related morning sickness. During this time, the compound quickly developed its infamous reputation as one of the most potent teratogenic substances ever promoted, as approximately 10,000 children were born with profound limb and internal organ abnormalities, later referred to as the "children of thalidomide." The compound was then banned until later research demonstrated novel applications to its poorly understood mechanism of action. In the 1990s, the drug was repurposed, as the FDA approved it to treat conditions such as erythema nodosum leprosum. This repurposing generated further research into understanding the drug's mechanisms and ultimately uncovered its effective anti-inflammatory, immunomodulatory and anti-angiogenic activities. Such properties have led to further FDA approval for the treatment of multiple myeloma. Thalidomide also has an orphan designation for the treatment for the following:
- Graft versus host disease
- Mycobacterial infection
- Severe recurrent aphthous stomatitis
- Primary brain malignancies
- HIV- associated wasting syndrome
- Crohn disease
- Kaposi sarcoma
- Myelodysplastic syndrome
- Hematopoietic stem cell transplantation
- Hereditary hemorrhagic telangiectasia.
Mechanism of Action
Thalidomide is a racemic glutamic acid analog with interchanging S(-) and R(+) enantiomers. The S(-) enantiomer directly inhibits the release of TNF-alpha, while the R(+) enantiomer acts as a sedative via sleep receptors. Spontaneous hydrolysis of thalidomide at physiologic PH results in the generation of approximately 20 different compounds. Metabolic enzymes act on these compounds to generate other active metabolites, which result in the inhibition of angiogenesis and endothelial cell proliferation.
Dosing of thalidomide is usually via the oral route with various strengths up to 200 mg tablets for all known treatment indications. However, some sources question the bioavailability of thalidomide after oral administration due to its spontaneous hydrolysis and incomplete absorption. Studies of intravenous administration demonstrate similar bioavailability to that of oral, while studies of other dosage forms could not be found. Thus, the development of novel drug delivery systems in the form of biodegradable thalidomide implants has been a topic of research.
Thalidomide treatment may be limited by its many adverse effects caused by numerous active metabolites derived from the degradation of its enantiomers. Common side effects include constipation, hypothyroidism, ACTH stimulation, hypoglycemia, xerostomia, fever, mood changes, headache, peripheral neuropathy, somnolence, sedation, rash, and deep vein thrombosis.
The use of thalidomide correlates with significant contraindications that physicians should consider before prescribing this compound. In particular, the FDA Black Box Warning involves embryo-fetal toxicity. If administered to a pregnant patient, thalidomide can cause severe congenital defects or death. Thus, clinicians must avoid using thalidomide in pregnant women or women who may become pregnant while taking the drug. Before initiating treatment with any amount of this drug, pregnancy must be excluded with two negative pregnancy tests and subsequently prevented with two reliable contraceptive methods. Prescribers of thalidomide must also receive certification with the THALOMID REMS program through enrollment and compliance with the REMS requirements.
A history of or significant risks to venous thromboembolic events represents another contraindication to the use of thalidomide therapy. Specifically, thalidomide increases the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients receiving treatment for multiple myeloma. This risk increases when using thalidomide in conjunction with chemotherapeutic agents such as dexamethasone. Because of this effect, patients treated with thalidomide therapy may also benefit from prophylactic anticoagulation or aspirin treatment.
Previous hypersensitivity reactions represent the final contraindication to thalidomide usage. Patients who previously displayed severe adverse events such as Stevens-Johnson syndrome or type 1 hypersensitivity reaction to this drug should no longer be considered candidates for therapy.
Proper monitoring of patients treated with thalidomide is essential to ensuring a safe and efficacious treatment, as this drug is related to numerous, potentially severe, adverse events and reactions. Despite questionable bioavailability via gastrointestinal absorption, almost all thalidomide therapy is delivered PO at dosages of 50-200 mg once daily. Thalidomide is absorbed slowly, with peak concentrations occurring within 2 to 5 hours after ingestion. Due to spontaneous hydrolysis at physiologic pH, >90% of thalidomide is renally excreted, with <5% of the drug being unchanged. The half-life of thalidomide is 5 to 7 hours, and toxicities may develop with increased dosage and duration of therapy. The most common symptoms related to thalidomide toxicity include constipation, sedation, fatigue, and neuropathy.
Monitoring of patients treated with thalidomide involves routine healthcare visits to the prescribing physicians. Clinicians may check patients for developing neuropathy via complete neurological exams or EMG studies every six months. Lab work monitoring is also necessary for the elevation of liver enzymes and thyroid function. Patients treated with thalidomide and dexamethasone should be observed for signs and symptoms of thromboembolism and instructed to seek medical care if they develop shortness of breath, chest pain, or arm or leg swelling. The patient should report any adverse reactions to the clinician (including increased somnolence, constipation, etc.). Lastly, both physician and patient should be enrolled in the STEPS program to ensure proper monitoring of compliance and adverse reactions (described further in the “toxicity” section).
There is no indicated antidote for thalidomide overdose. Thalidomide toxicity directly correlates with drug dosage and duration of therapy. Patients taking 200 mg or less appear to have good therapeutic outcomes without evident toxicity, while dosages exceeding 400 mg/day almost always lead to toxicity-related symptoms. The most common symptoms related to thalidomide toxicity include constipation, sedation, fatigue, and neuropathy. Therapy exceeding six months is associated with an increase in neuropathy and hypothyroidism related to thalidomide toxicity. However, the incidence of constipation and sedation seems to decrease with the continued duration of therapy. Thalidomide toxicity also seems to increase when used in conjunction with dexamethasone or other chemotherapy drugs. Of those receiving thalidomide and dexamethasone for multiple myeloma treatment, approximately 10% will discontinue the treatment due to toxicity-related effects.
Steps for addressing symptoms of thalidomide-related toxicity are listed below.
- Birth Defects
- All female patients with childbearing potential should receive two methods of contraception.
- All male patients should abstain from intercourse or use a condom - even those with a vasectomy.
- Both physician and patient should register for the S.T.E.P.S. program
- Peripheral neuropathy
- Mild: Decrease the thalidomide dose by 50%
- Moderate: Withhold thalidomide therapy until there is a resolution of toxicity and then restart at a 50% reduction
- Severe: Discontinue thalidomide therapy
- Instruct patients to administer their total daily dose before going to bed
- Patients should avoid driving or operating machinery
- In cases of stupor or coma, suspend thalidomide therapy until toxicity resolves, then restart treatment at a 50% dose
- Advise alteration of diet and exercise
- Start the patient on a low-dose stool softener or laxative
- In severe cases, withhold therapy until the condition resolves, then restart thalidomide with the addition of prophylactic laxative therapy and/or a 50% reduction in dose
- Skin rash
- Mild to moderate skin rash: withhold thalidomide until there is a resolution of the toxicity and then resume treatment at a 50% reduction in dosage
- Stevens-Johnson syndrome: discontinue therapy with no attempt to restart
- Orthostatic Hypotension
- The patient should sit upright for a few minutes before standing up from a recumbent position.
- All other toxicities
- Withhold thalidomide until toxicity resolves to baseline, then restart at a 50% reduction in drug dosage
- For all severe and life-threatening complications, discontinue thalidomide indefinitely.
Further steps for addressing thalidomide toxicity involve enrolling both physician and patient into the System for Thalidomide Education and Prescribing Safety (S.T.E.P.S) program. This program seeks to reduce misuse of thalidomide and thus mitigate adverse events (especially teratogenicity) via a three-pronged approach involving: access control, education of healthcare providers, pharmacists, and patients, and monitoring of compliance.
Enhancing Healthcare Team Outcomes
Management of therapeutic drugs with the potential for extreme adverse effects requires an interprofessional team, including clinicians, pharmacists, nurses, and social workers. Likewise, the management of toxicities involved with such drugs requires various other healthcare providers, including clinicians, pharmacists, nurses, and laboratory technicians. Studies demonstrate improved treatment outcomes and healthcare costs when therapy incorporates such interprofessional teams. [Level 1, Level 2]
The most common adverse effects of thalidomide therapy include constipation, sedation, fatigue, and neuropathy. Such effects are related to therapeutic dosage and duration and can affect patient compliance and therapeutic benefits. More serious effects include increased thrombus formation and hypersensitivity reactions. To avoid missed indications of toxicity, healthcare providers at all levels must monitor any related symptoms and advise appropriate alterations to therapy – especially when therapy involves combined treatment with dexamethasone. [Level 1]
Moreover, thalidomide is associated with extreme teratogenicity. As such, patients must enroll in the STEPS program, which involves a multidisciplinary team incorporating various healthcare specialists and social workers. [Level 4] This program allows for proper patient education and monitoring of patient safety and compliance.